ClinicalTrials.gg
CompletedNCT01844518Updated Jul 12, 2023Results posted

Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

A Phase 3 interventional study of Abatacept in Active Polyarticular Juvenile Idiopathic Arthritis, sponsored by Bristol-Myers Squibb. Completed at 57 sites in 12 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-07-12.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
219
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 109 studies in Arthritis, Juvenile with a site in United States — 20 open to participants now, 23 under way, 5 of them phase 3. Arthritis, Juvenile · United States.

Enrollment
8th of 83
219 · median 55
Started
2013
with 8 others
Phase 3
30 of 109
5 open now
Registered
55th of 109
by date
Lead sponsor
5 of 109
Bristol-Myers Squibb

Among the 109 studies in Arthritis, Juvenile with a site in United States, this one is the 8th largest by enrollment of the 83 interventional ones that give a count, is one of 9 that started in 2013, is one of 30 in phase 3, and was the 55th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

20 of the 109 studies in Arthritis, Juvenile with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Arthritis, Juvenile with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to estimate Abatacept steady-state trough concentration (Cmin) at Day 113 in children and adolescents with pJIA

03

Conditions studied

  • Active Polyarticular Juvenile Idiopathic Arthritis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • JIA subjects (male or female), ages 2-17 years with active disease who had an insufficient therapeutic response or intolerance to at least one non biologic DMARD or Tumor Necrosis Factor (TNFα) antagonists for at least 3 months prior to screening
  • Subjects with TNFα inadequate response (or prior biologic) will be restricted to 30% of the population
  • Subjects must have a history of at least 5 joints with active disease and must have currently active articular disease with ≥2 active joints and ≥2 joints with limitation of motion.

Exclusion criteria

Exclusion Criteria:

  • Subjects with other rheumatic diseases or major chronic inflammatory/immunologic diseases, active uveitis, systemic JIA with active systemic features (within a period of 6 months prior to enrollment), persistent Oligoarthritis JIA, or failed 3 or more TNFα antagonists or other biological DMARDs will be excluded.
  • Active systemic disease: (ie, extra-articular features of systemic JIA including fever, rash, organomegaly) within a period of 6 months prior to randomization.
  • Subjects who have failed more than two TNFα antagonists or other biologic DMARDs
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    Short and Long Terms: Orencia

    Short Term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 4 months Long term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 20 months

    Biological: Abatacept

Interventions

06

What researchers measure

Primary outcomes

  1. Abatacept Trough Concentration (Cmin) in Participants Ages 6 to 17

    Trough concentration of abatacept (reported as geometric mean of Cmin) in all pharmacokinetic (PK)-evaluable participants. Cmin is reported in microgram per milliliter (µg/mL). Desired target therapeutic Cmin should be \>= 10 µg/mL.

    Time frame: Day 113

Secondary outcomes

  1. Percentage of Participants (Ages 6 to 17) Achieving American College of Rheumatology Pediatric 30 Response (ACRp30)

    ACRp30 is defined as ≥30% improvement in at least 3 of the 6 juvenile idiopathic arthritis (JIA) core set variables: 1. number of active joints 2. number of joints with limitation of motion (LOM) 3. physician global assessment of disease activity 4. parent global assessment of patient overall well-being 5. functional ability as measured by the Children's Health Assessment Questionnaire (CHAQ) 6. C-reactive protein (CRP). In addition to the above condition, to be considered a responder participants cannot have ≥30% worsening in more than 1 of the 3 remaining JIA core set variables for which improvement was not observed.

    Time frame: Day 113

  2. Abatacept Trough Concentration (Cmin) in Participants Ages 6 to 17 by Weight Tier Dose

    Evaluation of the trough concentration of abatacept (reported as geometric mean of Cmin) in all pk-evaluable participants at Days 57, 85 and 113. Weight-tiered dosing groups are based on the first dose the participant received. Cmin is reported in microgram per milliliter (µg/mL). Here 'n' number analyzed signifies participants who were evaluable for each time point.

    Time frame: Days 57, 85 and 113

  3. Number of Participants With Adverse Events (AEs), Deaths, Serious AEs (SAEs) and AEs Leading to Discontinuation in the Short-Term Period for the 6-17 Year Age-Group Cohort

    An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product, whether or not considered related to the investigational product. A SAE is any untoward medical occurrence that at any dose which results in death, is life threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect.

    Time frame: From first dose up to 56 days post last dose in the short-term period (initial 4-month treatment period)

  4. Number of Participants With Adverse Events (AEs), Deaths, Serious AEs and AEs Leading to Discontinuation in the Cumulative Period

    An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product, whether or not considered related to the investigational product. A SAE is any untoward medical occurrence that at any dose which results in death, is life threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect.

    Time frame: From first dose up to 56 days after last dose ( up to approximately 2 years)

  5. Number of Participants With Positive Immunogenicity Response in the Short-Term Period for the 6-17 Year Age-Group Cohort

    Overall number of participants with either a positive immunogenicity response for 'CTLA4 and possibly Ig' or 'Ig and/or Junction Region' relative to baseline. Sample draws for immunogenicity were scheduled at specific study days while on treatment for all subjects and at follow-up visits 28, 85, and 168 days after the last abatacept dose for those subjects who discontinued from the short term (ST) period (initial 4-month treatment period) or completed the ST study without continuing abatacept treatment.

    Time frame: From first dose up to start of LT (for those continuing in long-term) or up to 168 days after the lost dose of study medication in the ST period (for those not entering in the long-term)

  6. Number of Participants With Positive Immunogenicity Response in the Cumulative Period

    Overall number of participants with either a positive immunogenicity response for 'CTLA4 and possibly Ig' or 'Ig and/or Junction Region' relative to baseline. Sample draws for immunogenicity were scheduled at specific study days while on treatment for all subjects and at follow-up visits 28, 85, and 168 days after the last abatacept dose regardless of whether they discontinued early in the short term (ST) or long term (LT) period, elected not to enter the LT period, or completed both ST and LT periods.

    Time frame: From first dose up to 6 months following treatment discontinuation (up to approximately 2 years)

07

Results

Posted Mar 24, 2016

Participant flow

Participant flow — Overall Study
MilestoneSC Abatacept Ages 6 to 17SC Abatacept Ages 2 to 5
Started17346
Completed13239
Not completed417
Withdrew: Adverse event71
Withdrew: Lack of efficacy175
Withdrew: Participant's request to discontinue41
Withdrew: Poor/non-compliance10
Withdrew: No longer met study criteria20
Withdrew: Withdrawal by subject90
Withdrew: Pregnancy10

Outcome measures

PrimaryAbatacept Trough Concentration (Cmin) in Participants Ages 6 to 17

Trough concentration of abatacept (reported as geometric mean of Cmin) in all pharmacokinetic (PK)-evaluable participants. Cmin is reported in microgram per milliliter (µg/mL). Desired target therapeutic Cmin should be \>= 10 µg/mL.

Time frame:
Day 113
Reported as:
Geometric mean · µg/mL
Abatacept Trough Concentration (Cmin) in Participants Ages 6 to 17
µg/mLSC Abatacept Ages 6 to 17
Abatacept Trough Concentration (Cmin) in Participants Ages 6 to 1739.7 ± 35
SecondaryPercentage of Participants (Ages 6 to 17) Achieving American College of Rheumatology Pediatric 30 Response (ACRp30)

ACRp30 is defined as ≥30% improvement in at least 3 of the 6 juvenile idiopathic arthritis (JIA) core set variables: 1. number of active joints 2. number of joints with limitation of motion (LOM) 3. physician global assessment of disease activity 4. parent global assessment of patient overall well-being 5. functional ability as measured by the Children's Health Assessment Questionnaire (CHAQ) 6. C-reactive protein (CRP). In addition to the above condition, to be considered a responder participants cannot have ≥30% worsening in more than 1 of the 3 remaining JIA core set variables for which improvement was not observed.

Time frame:
Day 113
Reported as:
Number · Percentage of participants
Percentage of Participants (Ages 6 to 17) Achieving American College of Rheumatology Pediatric 30 Response (ACRp30)
Percentage of participantsSC Abatacept Ages 6 to 17
Percentage of Participants (Ages 6 to 17) Achieving American College of Rheumatology Pediatric 30 Response (ACRp30)83.2 (77.7 to 88.8)
SecondaryAbatacept Trough Concentration (Cmin) in Participants Ages 6 to 17 by Weight Tier Dose

Evaluation of the trough concentration of abatacept (reported as geometric mean of Cmin) in all pk-evaluable participants at Days 57, 85 and 113. Weight-tiered dosing groups are based on the first dose the participant received. Cmin is reported in microgram per milliliter (µg/mL). Here 'n' number analyzed signifies participants who were evaluable for each time point.

Time frame:
Days 57, 85 and 113
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Abatacept Trough Concentration (Cmin) in Participants Ages 6 to 17 by Weight Tier Dose
microgram per milliliter (µg/mL)10 to <25 kg Dosing Group25 to <50 kg Dosing Group>=50 kg Dosing Group
Day 5729.5 ± 3236.2 ± 3533.0 ± 33
Day 8527.7 ± 3842.5 ± 3236.0 ± 40
Day 11334.3 ± 3944.2 ± 3436.6 ± 31
SecondaryNumber of Participants With Adverse Events (AEs), Deaths, Serious AEs (SAEs) and AEs Leading to Discontinuation in the Short-Term Period for the 6-17 Year Age-Group Cohort

An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product, whether or not considered related to the investigational product. A SAE is any untoward medical occurrence that at any dose which results in death, is life threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect.

Time frame:
From first dose up to 56 days post last dose in the short-term period (initial 4-month treatment period)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Deaths, Serious AEs (SAEs) and AEs Leading to Discontinuation in the Short-Term Period for the 6-17 Year Age-Group Cohort
ParticipantsSC Abatacept Ages 6 to 17
Deaths0
SAEs5
Drug-Related SAEs1
Discontinuation due to SAEs2
Overall AEs102
Drug-Related AEs36
Discontinuation due to AEs3
SecondaryNumber of Participants With Adverse Events (AEs), Deaths, Serious AEs and AEs Leading to Discontinuation in the Cumulative Period

An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product, whether or not considered related to the investigational product. A SAE is any untoward medical occurrence that at any dose which results in death, is life threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect.

Time frame:
From first dose up to 56 days after last dose ( up to approximately 2 years)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Deaths, Serious AEs and AEs Leading to Discontinuation in the Cumulative Period
ParticipantsSC Abatacept Ages 6 to 17SC Abatacept Ages 2 to 5
Deaths00
SAEs145
Drug-Related SAEs12
Discontinuation Due to SAEs40
Overall AEs15244
Treatment-Related AEs5430
Discontinuation Due to AEs71
SecondaryNumber of Participants With Positive Immunogenicity Response in the Short-Term Period for the 6-17 Year Age-Group Cohort

Overall number of participants with either a positive immunogenicity response for 'CTLA4 and possibly Ig' or 'Ig and/or Junction Region' relative to baseline. Sample draws for immunogenicity were scheduled at specific study days while on treatment for all subjects and at follow-up visits 28, 85, and 168 days after the last abatacept dose for those subjects who discontinued from the short term (ST) period (initial 4-month treatment period) or completed the ST study without continuing abatacept treatment.

Time frame:
From first dose up to start of LT (for those continuing in long-term) or up to 168 days after the lost dose of study medication in the ST period (for those not entering in the long-term)
Reported as:
Count of participants · Participants
Number of Participants With Positive Immunogenicity Response in the Short-Term Period for the 6-17 Year Age-Group Cohort
ParticipantsSC Abatacept Ages 6 to 17
Number of Participants With Positive Immunogenicity Response in the Short-Term Period for the 6-17 Year Age-Group Cohort3
SecondaryNumber of Participants With Positive Immunogenicity Response in the Cumulative Period

Overall number of participants with either a positive immunogenicity response for 'CTLA4 and possibly Ig' or 'Ig and/or Junction Region' relative to baseline. Sample draws for immunogenicity were scheduled at specific study days while on treatment for all subjects and at follow-up visits 28, 85, and 168 days after the last abatacept dose regardless of whether they discontinued early in the short term (ST) or long term (LT) period, elected not to enter the LT period, or completed both ST and LT periods.

Time frame:
From first dose up to 6 months following treatment discontinuation (up to approximately 2 years)
Reported as:
Count of participants · Participants
Number of Participants With Positive Immunogenicity Response in the Cumulative Period
ParticipantsSC Abatacept Ages 6 to 17SC Abatacept Ages 2 to 5
Number of Participants With Positive Immunogenicity Response in the Cumulative Period87

Adverse events

Collected over Participants were assessed for All-Cause Mortality from the date of their randomization until study completion (assessed up to approximately 113 months). SAEs and Other AEs were assessed from first dose to 168 days after last dose of study therapy (assessed up to approximately 113 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SC Abatacept Ages 6 to 170/173 (0%)18/173 (10.4%)127/173 (73.4%)
SC Abatacept Ages 2 to 50/46 (0%)6/46 (13%)44/46 (95.7%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventSC Abatacept Ages 6 to 17SC Abatacept Ages 2 to 5
TachycardiaCardiac disorders0/1731/46
Abscess limbInfections and infestations0/1731/46
CellulitisInfections and infestations0/1731/46
Molluscum contagiosumInfections and infestations0/1731/46
Hand fractureInjury, poisoning and procedural complications0/1731/46
Limb injuryInjury, poisoning and procedural complications0/1731/46
OverdoseInjury, poisoning and procedural complications0/1731/46
Tendon disorderMusculoskeletal and connective tissue disorders0/1731/46
Febrile convulsionNervous system disorders0/1731/46
Erythema multiformeSkin and subcutaneous tissue disorders0/1731/46
Most frequent other events
Showing 10 of 31
Most frequent other events
EventSC Abatacept Ages 6 to 17SC Abatacept Ages 2 to 5
NasopharyngitisInfections and infestations63/17320/46
PyrexiaGeneral disorders22/17315/46
Upper respiratory tract infectionInfections and infestations37/17312/46
CoughRespiratory, thoracic and mediastinal disorders10/17312/46
GastroenteritisInfections and infestations19/1739/46
RhinitisInfections and infestations13/1738/46
NauseaGastrointestinal disorders21/1737/46
VomitingGastrointestinal disorders13/1737/46
HeadacheNervous system disorders25/1737/46
Abdominal painGastrointestinal disorders16/1736/46

Baseline characteristics

All treated population included all participants who received at least one dose of study medication.

Age, Categorical
Age, Categorical(Participants)SC Abatacept Ages 6 to 17SC Abatacept Ages 2 to 5Total
<=18 years17346219
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)SC Abatacept Ages 6 to 17SC Abatacept Ages 2 to 5Total
Female13628164
Male371855
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SC Abatacept Ages 6 to 17SC Abatacept Ages 2 to 5Total
Black or African American14115
White14444188
More than one race000
Other15116
Weight
Weight(Participants)SC Abatacept Ages 6 to 17SC Abatacept Ages 2 to 5Total
<25 kg184361
25 to 50 kg74377
>=50 kg81081
08

Study locations

57 sites
  • Local Institution - 0007
    Birmingham, Alabama 35233-1711, United States
  • Local Institution - 0003
    Little Rock, Arkansas 72202, United States
  • Local Institution - 0011
    Hartford, Connecticut 06106, United States
  • Local Institution - 0009
    Chicago, Illinois 60637, United States
  • Riley Hospital For Children
    Indianapolis, Indiana 46202, United States
  • University Of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Local Institution - 0001
    Kansas City, Missouri 64108, United States
  • Local Institution - 0002
    Bronx, New York 10467, United States
  • Local Institution - 0008
    Cincinnati, Ohio 45229, United States
  • Local Institution - 0005
    Portland, Oregon 97227, United States
  • Local Institution - 0004
    Salt Lake City, Utah 84132, United States
  • Seattle Children'S Hospital
    Seattle, Washington 98105, United States
  • Local Institution - 0029
    Rosario, Santa FE 2000, Argentina
  • Local Institution - 0028
    San Miguel De Tucuman, Tucuman 4000, Argentina
  • Local Institution - 0030
    Buenos Aires, 1270, Argentina
  • Local Institution - 0064
    Caba, 1427, Argentina
  • Local Institution - 0031
    Cordoba, 5000, Argentina
  • Local Institution - 0037
    Bruxelles, 1200, Belgium
  • Local Institution - 0036
    Gent, 9000, Belgium
  • Local Institution - 0049
    Leuven, 3000, Belgium
  • Local Institution
    Curitiba, Parana 80250-060, Brazil
  • Local Institution - 0038
    Porto Alegre, Rio Grande Do Sul 91350-200, Brazil
  • Local Institution - 0042
    Sao Paulo, 04038-031, Brazil
  • Local Institution - 0040
    Sao Paulo, 05403-000, Brazil
  • Local Institution - 0041
    Sao Paulo, 05403-000, Brazil
  • Local Institution - 0018
    Bron Cedex, 69677, France
  • Local Institution - 0016
    Le Kremlin Bicetre Cedex, 94275, France
  • Local Institution - 0014
    Paris Cedex 15, 75743, France
  • Local Institution - 0017
    Poitiers, 86021, France
  • Local Institution - 0015
    Strasbourg Cedex, 67098, France
  • Local Institution - 0044
    Bad Bramstedt, 24576, Germany
  • Local Institution - 0045
    Berlin, 13353, Germany
  • Local Institution - 0046
    Hamburg, 22081, Germany
  • Local Institution - 0048
    Heidelberg, 69120, Germany
  • Local Institution - 0047
    Sankt Augustin, 53757, Germany
  • Local Institution - 0061
    Firenze, 50139, Italy
  • Local Institution
    Genova, 16147, Italy
  • Local Institution - 0022
    Milano, 20122, Italy
  • Local Institution - 0062
    Napoli, 80131, Italy
  • Local Institution - 0057
    Mexico City, Distrito Federal 06726, Mexico
  • Local Institution - 0059
    Mexico, Distrito Federal 06720, Mexico
  • Local Institution - 0060
    Guadalajara, Jalisco 44620, Mexico
  • Local Institution - 0056
    Monterrey, Nuevo Leon 64460, Mexico
  • Local Institution - 0058
    Merida, Yucatan 97133, Mexico
  • Local Institution - 0027
    Lima, 11, Peru
  • Local Institution
    Lima, 11, Peru
  • Local Institution - 0025
    Lima, 27, Peru
  • Local Institution - 0026
    Lima, 5, Peru
  • Local Institution - 0068
    Tolyatti, 445039, Russian Federation
  • Local Institution - 0035
    Park West, Bloemfontein, FREE State 9301, South Africa
  • Local Institution - 0032
    Pretoria, Gauteng 0002, South Africa
  • Local Institution - 0034
    Pretoria, Gauteng 0084, South Africa
  • Local Institution - 0033
    Cape Town, Western CAPE 7500, South Africa
  • Local Institution - 0050
    Barcelona, 08950, Spain
  • Local Institution - 0053
    Madrid, 28034, Spain
  • Local Institution - 0055
    Madrid, 28041, Spain
  • Local Institution - 0052
    Valencia, 46026, Spain
09

References and documents

Publications

  • Ruperto N, Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Cimaz R, Dare J, Espada G, Faugier E, Ferrandiz M, Gerloni V, Quartier P, Silva CA, Wagner-Weiner L, Gandhi Y, Passarell J, Nys M, Wong R, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. J Rheumatol. 2021 Jul;48(7):1073-1081. doi: 10.3899/jrheum.200154. Epub 2021 Jan 15. PubMed 33452173 ↗
  • Brunner HI, Tzaribachev N, Cornejo GV, Joos R, Gervais E, Cimaz R, Calvo Penades I, Cuttica R, Lutz T, Quartier P, Gandhi Y, Nys M, Wong R, Martini A, Lovell DJ, Ruperto N; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation. Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatr Rheumatol Online J. 2020 Feb 22;18(1):19. doi: 10.1186/s12969-020-0410-x. PubMed 32087715 ↗
  • Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Berman A, Calvo Penades I, Anton J, Avila-Zapata F, Cuttica R, Horneff G, Foeldvari I, Keltsev V, Kingsbury DJ, Viola DO, Joos R, Lauwerys B, Paz Gastanaga ME, Rama ME, Wouters C, Bohnsack J, Breedt J, Fischbach M, Lutz T, Minden K, Miraval T, Ally MMTM, Rubio-Perez N, Solau Gervais E, van Zyl R, Li X, Nys M, Wong R, Banerjee S, Lovell DJ, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study. Arthritis Rheumatol. 2018 Jul;70(7):1144-1154. doi: 10.1002/art.40466. Epub 2018 May 20. PubMed 29481737 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2013 to primary completion in Mar 2015, 18 months.

Results were first posted in Mar 2016, 1 year after primary completion.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2013
First posted
May 1, 2013
StartActual
Aug 30, 2013
Primary completionActual
Mar 12, 2015
CompletionActual
Feb 1, 2023
Results first posted
Mar 24, 2016
Last update
Jul 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01844518
Responsible party
Sponsor
First posted
May 1, 2013
Start date
Aug 30, 2013
Primary completion
Mar 12, 2015
Completion
Feb 1, 2023
Results posted
Mar 24, 2016
Last update
Jul 12, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion